Cite
HARVARD Citation
Tinker, A. et al. (n.d.). 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. International journal of gynecological cancer. p. A414. [Online].